vs
Side-by-side financial comparison of Aclarion, Inc. (ACON) and EXACT SCIENCES CORP (EXAS). Click either name above to swap in a different company.
EXACT SCIENCES CORP is the larger business by last-quarter revenue ($878.4M vs $18.5K, roughly 47536.6× Aclarion, Inc.). EXACT SCIENCES CORP runs the higher net margin — -9.8% vs -10223.7%, a 10214.0% gap on every dollar of revenue. On growth, Aclarion, Inc. posted the faster year-over-year revenue change (80.6% vs 23.1%). Over the past eight quarters, Aclarion, Inc.'s revenue compounded faster (35.2% CAGR vs 17.4%).
Aclarion, Inc. is a medical technology company focused on developing non-invasive solutions for chronic lower back pain diagnosis and treatment. Its core offerings leverage proprietary magnetic resonance spectroscopy technology to accurately identify painful intervertebral discs, serving healthcare providers and patients across the United States, with key focus on the chronic pain management and spinal care segments.
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
ACON vs EXAS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $18.5K | $878.4M |
| Net Profit | $-1.9M | $-86.0M |
| Gross Margin | 9.7% | 70.1% |
| Operating Margin | -10785.8% | -9.4% |
| Net Margin | -10223.7% | -9.8% |
| Revenue YoY | 80.6% | 23.1% |
| Net Profit YoY | 5.0% | 90.1% |
| EPS (diluted) | $1.39 | $-0.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.5K | $878.4M | ||
| Q3 25 | $18.9K | $850.7M | ||
| Q2 25 | $19.3K | $811.1M | ||
| Q1 25 | $19.0K | $706.8M | ||
| Q4 24 | $10.2K | $713.4M | ||
| Q3 24 | $14.4K | $708.7M | ||
| Q2 24 | $11.0K | $699.3M | ||
| Q1 24 | $10.1K | $637.5M |
| Q4 25 | $-1.9M | $-86.0M | ||
| Q3 25 | $-1.7M | $-19.6M | ||
| Q2 25 | $-1.6M | $-1.2M | ||
| Q1 25 | $-2.0M | $-101.2M | ||
| Q4 24 | $-2.0M | $-864.6M | ||
| Q3 24 | $-1.4M | $-38.2M | ||
| Q2 24 | $-1.2M | $-15.8M | ||
| Q1 24 | $-2.4M | $-110.2M |
| Q4 25 | 9.7% | 70.1% | ||
| Q3 25 | 23.2% | 68.6% | ||
| Q2 25 | 26.6% | 69.3% | ||
| Q1 25 | -23.6% | 70.8% | ||
| Q4 24 | -100.9% | 69.0% | ||
| Q3 24 | -48.1% | 69.4% | ||
| Q2 24 | -112.3% | 69.8% | ||
| Q1 24 | -92.6% | 70.0% |
| Q4 25 | -10785.8% | -9.4% | ||
| Q3 25 | -9666.2% | -3.0% | ||
| Q2 25 | -8988.6% | -0.3% | ||
| Q1 25 | -7856.0% | -13.6% | ||
| Q4 24 | -17652.7% | -122.8% | ||
| Q3 24 | -8995.3% | -5.6% | ||
| Q2 24 | -10350.6% | -3.8% | ||
| Q1 24 | -12609.3% | -16.7% |
| Q4 25 | -10223.7% | -9.8% | ||
| Q3 25 | -9008.0% | -2.3% | ||
| Q2 25 | -8285.9% | -0.1% | ||
| Q1 25 | -10728.4% | -14.3% | ||
| Q4 24 | -19444.6% | -121.2% | ||
| Q3 24 | -9482.7% | -5.4% | ||
| Q2 24 | -11285.0% | -2.3% | ||
| Q1 24 | -23720.6% | -17.3% |
| Q4 25 | $1.39 | $-0.45 | ||
| Q3 25 | $-2.93 | $-0.10 | ||
| Q2 25 | $-2.75 | $-0.01 | ||
| Q1 25 | $-9.32 | $-0.54 | ||
| Q4 24 | $-809.36 | $-4.69 | ||
| Q3 24 | $-1321.49 | $-0.21 | ||
| Q2 24 | $-1362.83 | $-0.09 | ||
| Q1 24 | $-3985.22 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.0M | $964.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $12.8M | $2.4B |
| Total Assets | $13.7M | $5.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.0M | $964.7M | ||
| Q3 25 | $11.3M | $1.0B | ||
| Q2 25 | $12.8M | $858.4M | ||
| Q1 25 | $14.8M | $786.2M | ||
| Q4 24 | $453.7K | $1.0B | ||
| Q3 24 | $1.3M | $1.0B | ||
| Q2 24 | $1.2M | $946.8M | ||
| Q1 24 | $2.1M | $652.1M |
| Q4 25 | $12.8M | $2.4B | ||
| Q3 25 | $12.5M | $2.5B | ||
| Q2 25 | $14.2M | $2.5B | ||
| Q1 25 | $15.8M | $2.4B | ||
| Q4 24 | $970.1K | $2.4B | ||
| Q3 24 | $2.5M | $3.2B | ||
| Q2 24 | $1.6M | $3.2B | ||
| Q1 24 | $2.5M | $3.1B |
| Q4 25 | $13.7M | $5.9B | ||
| Q3 25 | $13.2M | $5.9B | ||
| Q2 25 | $14.8M | $5.8B | ||
| Q1 25 | $16.5M | $5.7B | ||
| Q4 24 | $2.1M | $5.9B | ||
| Q3 24 | $3.2M | $6.7B | ||
| Q2 24 | $3.1M | $6.7B | ||
| Q1 24 | $3.7M | $6.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $151.7M |
| Free Cash FlowOCF − Capex | — | $120.4M |
| FCF MarginFCF / Revenue | — | 13.7% |
| Capex IntensityCapex / Revenue | — | 3.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $356.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.6M | $151.7M | ||
| Q3 25 | $-1.2M | $219.9M | ||
| Q2 25 | $-1.9M | $89.0M | ||
| Q1 25 | $-2.5M | $30.8M | ||
| Q4 24 | $-922.9K | $47.1M | ||
| Q3 24 | $-1.1M | $138.7M | ||
| Q2 24 | $-1.1M | $107.1M | ||
| Q1 24 | $-2.2M | $-82.3M |
| Q4 25 | — | $120.4M | ||
| Q3 25 | $-1.2M | $190.0M | ||
| Q2 25 | — | $46.7M | ||
| Q1 25 | — | $-365.0K | ||
| Q4 24 | — | $10.7M | ||
| Q3 24 | — | $112.6M | ||
| Q2 24 | — | $71.2M | ||
| Q1 24 | — | $-120.0M |
| Q4 25 | — | 13.7% | ||
| Q3 25 | -6164.6% | 22.3% | ||
| Q2 25 | — | 5.8% | ||
| Q1 25 | — | -0.1% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | — | 15.9% | ||
| Q2 24 | — | 10.2% | ||
| Q1 24 | — | -18.8% |
| Q4 25 | — | 3.6% | ||
| Q3 25 | 38.6% | 3.5% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | 0.0% | 3.7% | ||
| Q2 24 | — | 5.1% | ||
| Q1 24 | — | 5.9% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACON
Segment breakdown not available.
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
